《Clarivate：2024年暂未引发关注的ADC创新公司报告（56页）.pdf》由会员分享，可在线阅读，更多相关《Clarivate：2024年暂未引发关注的ADC创新公司报告（56页）.pdf（56页珍藏版）》请在本站上搜索。 1、ADC202427ADC040607ADC102023ADC16ADC19ADC2324 Adcendo ApS28 Araris Biotech AG32 GO Therapeutics36 Heidelberg Pharma AG41 Pheon Therapeutics45 Tallac Therapeutics,Inc49 Tubulis 53ADC IPADCBioWorldCortellisCortellisCortellisCortellisOFF-X4AIDTSR5Matthew Arnold Shilpa Bali Yanbing Bertho John Borgman So2、nia Giral Lopez Padma Sekhar Mike Ward Angela Weidner(ADC)ADCADC(Pzer Inc)430Seagen Inc(AbbVie)100ImmunoGen(Johnson&Johnson)20Ambrx Biopharma Inc(mAb)ADCmAbADCADCADCADCADC(CDMO)ADCADCADC6ADC601202403ADC10ADC(MoA)ADCADCADCADCADCADCADCADCADCADCADC7ADC(RWE HEOR)ADCADCADCADCADC(IP)ADC8ADCADC5ADC92023ADC3、ADC15331020231220ADCifinatamab deruxtecanpatritumab deruxtecanraludotatugderuxtecan420227ADC2022515ADC12010080604020040353025201550Cortellis102020202120222023201910152019-202310patritumabderuxtecan(HER3 DXd)inifituzumabderuxtecan(I DXd)raludotatugderuxtecan(R DXd)22 02023 10 197ADC9 52022 12 22DXdAD4、CDS 8201(trastuzumabderuxteca)(NSCLC)6 92019 03 28DS 1062(datopotamabderuxtecanNSCLC(TNBC)6 02020 07 27GenmabA SGenmabepcoritamab(DuoBody CD3xCD20)DuoHexaBody CD37DuoBody CD3x5T43 92020 06 10NurixTherapeuticsIncSeagenIncNurixTherapeuticsDELigase(DAC)3 52023 09 07SeagenInc(SeattleGenetics)ladiratuzum5、abvedotin3 22020 09 14MORAb 2023 12021 06 17RemeGenCoLtdSeagenIncdisitamabvedotin(RC 48)2 62021 08 09BB 17012 02023 05 08Synafix B VSynaffixADCSynaffixB V42 02023 01 05Cortellis112024412202432ADC5 Systimmune84BL B01D1NSCLC2024417 Caris Discovery14ADC 202444 MediLink Therapeutics10MediLink Therapeuti6、csYL 211202412 Sutro Biopharma IncIpsen8 99STRO 003202442515ADC2023750%430Seagen22420221215(COVID 9)Seagen(PfizerInc)114FDAADCETRISPADCEVenfortumabvedotin TIVDAKtisotumabvedotinADCTUKYSAtucatinibTKI2030100202441220243ADC ImmunoGen1012024212 Ambrx Biopharma Inc20202437 Genmab A S18202443252019-2023AD7、C10SeagenInc43 02023 12 14ImmunomedicsInc21 02020 10 23VelosBio2 82020 12NBE Therapeutics1 42020 12 10Synafix B V0 22023 06 02Cortellis12ADCADC232102014-2023ADC53102014-2023ADC5CortellisCortellisADC Therapeutics SALegoChem Bioscience IncSynafix BVHeidelberg PharmaHolding GmbH/Seagan IncLegoChem Bios8、cience IncNational Institutes of Health NIHImmunoGen IncBolt BiotherapeuticsIncSesen Bio IncADC Therapeutics SAImmunoGen IncMD Anderson Cancer CenterNational Institutes of HealthNIHMemorial Sloan KetteringCancer CenterSutro Biopharma Inc13ADCCDMOADCCDMO4ADC5ADC4ADCCDMOCortellis20244AvidBioservicesIn9、c02461357LegoChemBioscienceCoLtdRigaChemBioscienceCoLtdGeneQuantumHealthcareSamsungBiologicsTOTBIOPHARMAbTisDong ASTAbzenaADCTherapeuticsSA1412181163981262316205102014 2023ADC3ADC2014-2023392205 719 19805 63415 01870 011420 01555 08384 245 3ADCCortellisCortellis15ADC1200ADC56652019-2023ADCCortellis610、0050040030020010000II IIIIII IIIIIIIVN ASeagen IncSeagen7167ADCCortellis20244080401202010060140160200180ADC Therapeutics SATakeda OncologySeagen IncMD Anderson Cancer CenterImmunoGen17ADC8ADC513ADCAMDAL()(NASH)Kodiak Sciences IncAMDKSI 501III202468ADCCortellis202440841221061614CidaraTherapeuticsIncZ11、ymeworksIncBioAtlaIncHeidelbergPharmaAGADCTherapeuticsPyxisOncology184ADCADCMYLOTARGgemtuzumabozogamicinCD33NAcButDMHDNA200920005(R R)CD33(AML)ADCETRISCD30E(MMAE)Mc Val CitPABCSeagenInc 202312MillenniumPharmaceuticalsInc2008420118R R(ALCL)ALCLCD30TKADCYLAHER2DM1SMCC20132HER2BESPONSAinotuzumabozogami12、cinCD22NAcButDMHDNA20176R R(ALL)19ADC2010ADC4ADC20189ADCEMAADCLUMOXITImoxetumomabpasudotoxCD22PE38Mc Val Cit PABCEEF2K20189(HCL)POLIVYpolatuzumabvedotinCD79bMMAEMc Val Cit PABC20196R RB(DLBCL)PADCEVenfortumabvedotinNectin 4MMAEMc Val Cit PABCSeagenInc201912ENHERTUfamtrastuzumabderuxtecanHER2DX 8951D13、XdMc Gly Gly PheGlyDNA1TOP1201912HER2HER2NSCLCHER2TRODELVYsacituzumabgovitecanTROP2SN 38CL2ADNATOP1Immunomedics2020920204BLENREPbelantamabmafadotinBBCMAF MEAF20208R RAkalux(cetuximabsarotalocanEGFRIRDye700DX(20209ZYNLONTAloncastuximabtesirineCD19SG3199Mal PEG8 Val Ala PABC(DNAADCTherapeutics20214LBC14、LDLBCAidixidisitamabvedotinHER2 MMAEMc Val Cit PABC20216TIVDAKtisotumabvedotinMMAEMc Val Cit PABCSeagen202312GenmabA S20219ELAHEREmirvetuximabsoravtansineFRDM4sulfo SPDBDNAImmunoGen20242202211FR20ADC12 18FDAEMA2024ADCdatopotamab deruxtecan(Dato DXd)BLA(MAA)6 7Dato DXd20248(HR)HER2NSCLCPDUFA20251292015、241220DatoDXDTROP2ADCTRODELVYHRHER2Dato DXDDXD ADC6ADCADCTropion Breast01Tropion Lung01III(PFS)ADC Patritumab deruxtecanBLAFDAPDUFA2024626202312MSD9FDA202112IIHERTHENA Lung01HER3DXd ADCpatritumabderuxtecanEGFRNSCLCBLAADCtusamitamab ravtansineIIICarmen LC03(PFS)10(OS)NSCLC2024tusamitamabADCADCADCFDA216、0243ADC11ADCQTcFDAADC910 ADCADC ADC ADC ADC219ADC10ADCOFF-XOFF-X221.Adcendo ApS Niels BehrendtLars EngelholmChristoffer NielsenHenrik Stage2.Araris Biotech AG Dragan GrabulovskiPhilipp SpycherIsabella Attinger-TollerMartin BeheRoger Schibli3 GO TherapeuticsConstantine TheodoropulosHansWandall4 Heide17、lberg Pharma AGEmerged from two companies7 TubulisDominik SchumacherJonas Helma SmetsIngo LehrkeChristian Hackenberger Heinrich Leonardt5.Pheon Therapeutics David Thurston Paul Jackson6 Tallac Therapeutics IncHong WanCoreyGoodmanJaume Pons Curt Bradshaw6554231723 Gilde Healthcare HealthCap Novo Hold18、ings Pontifax Venture Capital RA Capital Management Ysios CapitalAdcendo ApSFinsen(BII)2021AADC(FIC)uPARAP(STS)(GIST)uPARAPuPARAPADC2017Niels BehrendtLars EngelholmChristofer NielsenHenrik Stage24Duality BiologicsAdcendoDuality BiologicsDITAC DualityuPARAP ADCADCADC FICADC ADCADC STS2024 2024INDFins19、enADCuPARAPuPARAPADCADCuPARAPSTS25 AdcendoFIC ADC uPARAP ADCMoACDXPDXIND 2024STSuPARAPADCI 2024FIC FIC ADC 20234A3100Pontifax Venture CapitalNovo HoldingsYsios CapitalRA Capital ManagementHealthCapGilde Healthcare20214A5100Novo HoldingsNovo SeedsYsios CapitalGlideHealthcare HealthCapRACapital Manage20、ment26ADCADCAdcendoADCMichael Pehl,Adcendo ApS27Araris Biotech(ETH Zurich)(Paul Scherrer Institute)ADCArarisADCADCADC2019Dragan GrabulovskiPhilipp SpycherIsabella Attinger TollerMartin BeheRoger SchibliAu 4BIO Capital Pureos Bioventures VI Partners Redalpine Samsung Ventures Schroder Adveq btov Part21、ners Institute for Follicular Lymphoma Innovation Wille Finance28Taiho Pharmaceutical CoArarisTaiho PharmaceuticalCoADC ArarisADC(DAR)8(PEG)ArarisADC ArarisADC ADCArarisADCADC2930 ArarisADCADC ADC ADCNHP 2023MMAENectin 4ADC2024TOP1iADCADCHER2NaPi2bTOP1i Araris BiotechADC 20235Innosuisse2502023 4 C T22、202210A24004BIOCapitalPureosBioventuresRedalpineSchroderAdveqVIPartnersbtovPartnerstheInstituteforFollicularLymphomaInnovationWilleAG2020101270PureosBioventures4BIO Capitalbtov PartnersRedalpineSchroderAdveqVIPartners20198250RedalpineSchroderAdveqVI Partners20196VentureKick1331ADCADCADCFDA ADCADCADC23、Philipp Spycher PhDAraris Biotech3132GO TherapeuticsFIC2014Constantine TheodoropulosHans Wandall Salubris Pharmaceutical Limited33CD44v6CAR TXyphos Biosciences Inc OO60 80%700OOOTnSTn GO Therapeutics ECMADC GO 13C3GO 8H3GO STnGO C15TTCBCAR T34 O GO Therapeutics GO TherapeuticsADC20245IND GO Therapeu24、tics8 20179Salubris Pharmaceutical Limited 50035GOGOADCConstantine TheodoropulosGO Therapeutics3536Heidelberg PharmaADCATACATACADCADCRNAII2014 Heidelberg Pharma Dietmar Hopp Biotech Holding Freefloat37TACT11ADCPHioniCpHNTEGRATANADNADADCBCMA(PSMA)MD17pHealthCare RoyaltyHealthCare Royalty(HCRx)Zircaix25、(TLX250CDx 89Zr DFOgirentuximab)Zircaix(PET)HDP 101HDP 103ADCRedHill Biopharma LtdRedHill Biopharma Ltdupamostat(RHB 107)upamostatuPATelix Pharmaceuticals LimitedTLX250 CDxTLX250CDx(Zircaix)TLX250 CDx(Zircaix)38 Heidelberg Pharma AGADC2014WILEX AGHeidelberg PharmaResearchGmbHWILEXAGHeidelberg Pharma26、ResearchGmbHADC HeidelbergPharmaATACATAC ADC ADCDNARNAIIADC ATACHDP 101BCMA ATACHDP 102CD37ATACHDP 103ATAC SCATACSCATACATACADCADC ATAC HDP 101MDCBCMA Heidelberg PharmaATACATAC Heidelberg PharmaIADC 2023HDP101IIIa20243839 Heidelberg PharmaADC ATACADC20222800020216200020204144020199(ETN)MAGICBULLET He27、idelbergPharmaHDP 101IIIa6 HDP 10120243FDA HDP 102HDP 103 HDP 201 ATAC ATAC ADCENHERTUHER2 ATAC ATACATAC 17p500 ATACHeidelbergPharma MDRNAII 40Andreas Pahl Heidelberg Pharma4041Pheon Therapeutics(ADC)ADCADCPHN 01020242015David Thurston Paul Jackson Atlas Venture Brandon Capital Forbion Research Corp28、oration Technologies(RCT)BVF Partners Lightspeed Perceptive Advisors42PheonRenMiceADC 2024 ADC PHN 0102024DAR8 TOP1i43 ADC20245B1 2TCGXBVF PartnersLightspeedPerceptive AdvisorsAtlas VentureBrandon CapitalForbionResearch Corporation Technologies(RCT)20229A6800Brandon CapitalForbionAtlas VentureRCT PH29、N 010NHP PheonADC44PheonCyrus Mozayeni,MD;Pheon Therapeutics4445TallacTherapeutics(ADC)(AOC)Toll(TRAAC)Toll(TLR9)(T CpG)AOC2020Hong WanCorey GoodmanJaume PonsCurt Bradshaw Lightstone Ventures Merck MorningsideVenture venBio Partners46 Tallac TherapeuticsAOCAOC TRAACT CpG TAC 001ALX OncologyTallac Th30、erapeuticsALTA 002(SIRPTRAAC)47 TallacAOC TAC 001PD 1CTLATAC 001202012A6200venBio PartnersMorningsideVentureLightstoneVenturesMatrixPartnersChinaMRLVenturesFund TAC 001CD22TLR9BI TAC 001 ALTA 002SIRP TLR92024(FIH)TAC 003INDTAC 003Nectin 4 COM48TallacADCTallacADCADCHong WanTallac Therapeutics48Tubuli31、s(LMU)ADCTub tagP5ADC2019Dominik SchumacherJonas Helma SmetsIngo LehrkeChristian HackenbergerHeinrich Leonardt Andera Partners BayernKapital BioMedPartners coparion Deep TrackCapital EQT Life Sciences Evotec FrazierLife Sciences Fund High Tech Grnderfonds(HGTF)NextechInvest Ltd OCCIDENT Seventure Pa32、rtners49(FMP)(LMU)TubulisTubutecanP5ADCOncoteq AQTubulisADC TUB 010TEQ102CD30T50 TubulisADCChristianHackenberger(FMP)Heinrich Leonhardt(LMU)Dr Jonas Helma Smets 20ADCADC TubulisADCADCTub tagADCP5 Tubulis Tubulis51 ADC Tubulis TUB 040TUB 030TUB 040Napi2bTUB 0305T4 TUB 040TUB 030 2024III TUB 050TUB 0633、0 20243B21 388EQT Life SciencesNextechInvest LtdFrazierLife SciencesDeep Track CapitalAndera PartnersBioMedPartnersFundBayernKapitalScaleUp Fonds BayernEvoteccoparionSeventurePartnersOCCIDENTHTGFSciencesDeep Track CapitalAndera PartnersBioMedPartnersFundBayern KapitalScaleUpFonds BayernEvoteccopario34、nSeventurePartnersOCCIDENTHTGF20225Andera PartnersB6300EvotecFundBayern KapitalWachstumsfonds Bayern2BioMedPartnerscoparionHTGFOCCIDENTSeventurePartners20207A1070BioMedPartnersHTGFSeventure PartnerscoparionBayern KapitalOCCIDENT52TubulisADCADCDominik Schumacher,PhD;Tubulis52535ADCADCADCADCADC541DeCa35、rvalho S Rand HJ Lewis A Coupling of cyclic chemotherapeutic compounds toimmune gamma globulins Nature 1964 202 255 8 doi 10 1038 202255a02Ford CH Newman CE Johnson JR et al Localisation and toxicity study of avindesine anti CEA conjugate in patients with advanced cancer Br J Cancer1983 47 35 423Nor36、sworthy KJ Ko CW Lee JE Let al FDA approval summary Mylotarg for treatmentof patients with relapsed or refractory CD33 positive acute myeloid leukemiaOncologist 2018 23(9)1103 1108 doi 10 1634 theoncologist 2017 06044BioWorld October 24 2023 Merck agrees to pay Daiichi up to 22B in recordADC agreeme37、ntOnline Available at www bioworld com articles 702163 merckgreesto pay daiichi up to 22b in record adcagreement Accessed March 22 20245BioWorld March 13 2023 Pfizer to buy Seagen for 43BOnline Available atwww bioworld com articles 695053 pfizer to buy seagen for 43bAccessed March 19 20246BioWorld A38、pril 3 2024 FDA accepts Daiichi Astrazeneca s BLA for Trop2 breast cancerdrugOnline Available at www bioworld com articles 707240 fda accepts daiichiastrazenecas bla for trop2 breast cancer drug Accessed May 3 20247BioWorld March 4 2024 EMA validates two filings for Daiichi Astrazeneca s ADCOnline A39、vailable at www bioworld com articles 706191 ema validates two filingsfor daiichi astrazenecas adc Accessed May 3 20248Clarivate Drugs to WatchOnline Available at clarivate com drugs to watchAccessed May 3 20249MSD December 22 2023 Patritumab Deruxtecan Granted Priority Review in the U Sfor Certain 40、Patients with Previously Treated Locally Advanced or Metastatic EGFRMutated Non Small Cell Lung CancerOnline Available at www merck com newspatritumab deruxtecan granted priority review in the u s for certain patients withpreviously treated locally advanced or metastatic egfr mutated non small cell 41、lungcancerAccessed May 3 202410BioWorld December 22 2023 Antibody drug tusamitamab ravtansine fails in phase IIISanofi bows outOnline Available at www bioworld com articles 704110 antibodydrug tusamitamab ravtansine fails in phase iii sanofi bows out Accessed May 3 202411FDA March 2024 ClinicalPharmacologyConsiderationsfor Antibody Drug ConjugatesGuidance for IndustryOnline Available at www fda gov media 155997 downloadAccessed May 2 2C61010019086 10 5760120086 10 82862088info chinaclarivate 2024 ClarivateBXD1472768005/02